SWK Holdings Corporation
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SWK Holdings Corporation (Nasdaq: SWKH), a life science-focused specialty finance company, partners with small- and mid-sized commercial-stage healthcare companies to provide minimally dilutive financing solutions that fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products; its core offerings include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging from $5.0 million to $25.0 million, with a focus on sub-$50M opportunities in healthcare, biopharma, medical devices, diagnostics, life science tools, and healthcare services. The company deploys capital through its own balance sheet and investment advisory clients, including family offices and institutional investors, targeting early-stage, seed/startup, Series A to Series D, and growth capital investments in the global healthcare sector; it conducts thorough due diligence encompassing clinical data review, competitive environment analysis, financial modeling, market strategy review, industry expert consultation, and IP review to tailor solutions that preserve partners' ownership interests. Founded in 1996 and headquartered in Dallas, Texas, SWK Holdings generates superior risk-adjusted returns for investors by investing in marketed ethical product cash flow streams and has completed financings with over 55 parties, deploying approximately $780 million of capital since inception. Recent developments include the sale of its majority royalty portfolio, including an Iluvien royalty buyout by ANI Pharmaceuticals for $17.3 million in March 2025 and an agreement with Soleus Capital for its remaining performing royalties for $34.0 million; new financings such as a $15 million commitment to Impedimed, a $30 million expanded credit facility with Eton Pharmaceuticals, advances to Journey Medical, Biotricity, Triple Ring Technologies, and SKNV, and MedMinder; the sale of MOD3 subsidiary assets post-Q4 2024; a $4.00 per share dividend payment; share repurchases totaling approximately $2.2 million in 2025; strong Q3 2025 financial results with $10.9 million in revenue; and, most notably, a definitive merger agreement announced in October 2025 with Runway Growth Finance Corp. for an estimated $220 million NAV-for-NAV transaction to enhance portfolio diversification in healthcare and life sciences.
Company News
Here's Why Stanley Black & Decker (SWK) is a Strong Value Stock
Why Is Stanley Black & Decker (SWK) Up 3.9% Since Last Earnings Report?
SWK vs. TTNDY: Which Stock Should Value Investors Buy Now?
Stanley Black & Decker (SWK) Just Flashed Golden Cross Signal: Do You Buy?
Why Stanley Black & Decker (SWK) is a Top Value Stock for the Long-Term
Here's Why Stanley Black & Decker (SWK) is a Strong Momentum Stock
Stanley Black & Decker, Inc. (SWK) Q2 2026 Earnings Call Transcript
Compared to Estimates, Stanley Black & Decker (SWK) Q2 Earnings: A Look at Key Metrics
Stanley Black & Decker (SWK) Q2 Earnings and Revenues Surpass Estimates
Stanley Black & Decker (SWK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Here's Why Stanley Black & Decker (SWK) is a Strong Value Stock
Here's Why Stanley Black & Decker (SWK) is a Strong Momentum Stock
Will Stanley Black & Decker (SWK) Beat Estimates Again in Its Next Earnings Report?
Here's Why Stanley Black & Decker (SWK) is a Strong Value Stock
Why Stanley Black & Decker (SWK) is a Top Momentum Stock for the Long-Term
Stanley Black & Decker, Inc. (SWK) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
Why Stanley Black & Decker (SWK) is a Top Value Stock for the Long-Term
Why Is Stanley Black & Decker (SWK) Up 1.4% Since Last Earnings Report?
Here's Why Stanley Black & Decker (SWK) is a Strong Value Stock
Stanley Black & Decker (SWK) Just Reclaimed the 200-Day Moving Average